title: Comparative effects of 1α-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on transporters and enzymes in fxr(+/+) and fxr(-/-) mice.
abstract: Previous studies have shown that 1α,25-dihydroxyvitamin D3 [1,25(OH)2 D3 ] treatment in mice resulted in induction of intestinal and renal Cyp24a1 and Trpv6 expression, increased hepatic Cyp7a1 expression and activity, as well as higher renal Mdr1/P-gp expression. The present study compared the equimolar efficacies of 1α-hydroxyvitamin D3 [1α(OH)D3 ] (6 nmol/kg i.p. q2d × 4), a lipophilic precursor with a longer plasma half-life that is converted to 1,25(OH)2 D3 , and 1,25(OH)2 D3 on vitamin D receptor (VDR) target genes. To clarify whether changes in VDR genes was due to VDR and not secondary, farnesoid X receptor (FXR)-directed effects, namely, lower Cyp7a1 expression in rat liver due to increased bile acid absorption, wildtype [fxr(+/+)] and FXR knockout [fxr(-/-)] mice were used to distinguish between VDR and FXR effects. With the exception that hepatic Sult2a1 mRNA was increased equally well by 1α(OH)D3 and 1,25(OH)2 D3 , 1α(OH)D3 treatment led to higher increases in hepatic Cyp7a1, renal Cyp24a1, VDR, Mdr1 and Mrp4, and intestinal Cyp24a1 and Trpv6 mRNA expression in both fxr(+/+) and fxr(-/-) mice compared to 1,25(OH)2 D3 treatment. A similar induction in protein expression and microsomal activity of hepatic Cyp7a1 and renal P-gp and Mrp4 protein expression was noted for both compounds. A higher intestinal induction of Trpv6 was observed, resulting in greater hypercalcemic effect following 1α(OH)D3 treatment. The higher activity of 1α(OH)D3 was explained by its rapid conversion to 1,25(OH)2 D3 in tissue sites, furnishing higher plasma and tissue 1,25(OH)2 D3 levels compared to following 1,25(OH)2 D3 -treatment. In conclusion, 1α(OH)D3 exerts a greater effect on VDR gene induction than equimolar doses of 1,25(OH)2 D3 in mice.
authors.affiliation: Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada, M5S 3 M2.
authors.forename: Edwin C Y
authors.initials: EC
authors.lastname: Chow
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Durk
authors.forename: Han-Joo
authors.initials: HJ
authors.lastname: Maeng
authors.forename: K Sandy
authors.initials: KS
authors.lastname: Pang
mesh_terms: D000818:Animals; D002117:Calcitriol / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D002118:Calcium / Q000097:blood; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism; D006887:Hydroxycholecalciferols / Q000493:pharmacokinetics / Q000494:pharmacology*; D007082:Ileum / Q000187:drug effects / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D026901:Membrane Transport Proteins / Q000235:genetics; D051379:Mice; D018345:Mice, Knockout; D010758:Phosphorus / Q000097:blood; D018167:Receptors, Calcitriol / Q000235:genetics*; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics*; D015238:Sulfotransferases / Q000235:genetics; D000099150:Receptor, Farnesoid X-Activated
chemical_list: D002117:Calcitriol; D002118:Calcium; D003577:Cytochrome P-450 Enzyme System; D006887:Hydroxycholecalciferols; D026901:Membrane Transport Proteins; D010758:Phosphorus; D018167:Receptors, Calcitriol; D018160:Receptors, Cytoplasmic and Nuclear; D015238:Sulfotransferases; D000099150:Receptor, Farnesoid X-Activated; C028152:alcohol sulfotransferase; C008088:alfacalcidol
keywords: 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3]; 1α-hydroxyvitamin D3 [1α(OH)D3]; enzymes; transporters; vitamin D receptor (VDR)